Verastem, Inc. (VSTM) 10-Year Financial Performance & Capital Metrics

VSTM • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutVerastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.Show more

Revenue $10M
EBITDA -$115M -24.9%
Net Income -$131M -49.5%
EPS (Diluted) -3.66 +7.6%
Gross Margin 100%
EBITDA Margin -1149.3%
Operating Margin -1149.56%
Net Margin -1306.37%
ROE -917.36% -450.0%
ROIC -
Debt/Equity -
Interest Coverage -25.20 -13.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 10.5% over 5 years
✗Shares diluted 61.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-10.54%

3Y69.51%

TTM33.79%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-157.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM-45.14%

ROCE

10Y Avg-72.56%

5Y Avg-78.91%

3Y Avg-100.48%

Latest-118.57%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	26.72M	17.46M	88.52M	2.05M	2.6M	0	10M
Revenue Growth %	-	-	-	-	-0.35%	4.07%	-0.98%	0.26%	-1%	-
Cost of Goods Sold+	754K	670K	556K	588K	2.81M	33.74M	0	0	0	0
COGS % of Revenue	-	-	-	0.02%	0.16%	0.38%	-	-	-	-
Gross Profit+	-754K	-670K	-556K	26.13M	14.65M	54.77M	2.05M	2.6M	0	10M
Gross Margin %	-	-	-	0.98%	0.84%	0.62%	1%	1%	-	1%
Gross Profit Growth %	-	0.11%	0.17%	48%	-0.44%	2.74%	-0.96%	0.26%	-1%	-
Operating Expenses+	58.2M	37M	67.8M	120.91M	146.99M	104.13M	63.46M	75.53M	92.08M	124.96M
OpEx % of Revenue	-	-	-	4.53%	8.42%	1.18%	30.91%	29.1%	-	12.5%
Selling, General & Admin	17.63M	17.22M	21.38M	77.27M	101.21M	62.76M	24.11M	24.98M	30.73M	43.62M
SG&A % of Revenue	-	-	-	2.89%	5.8%	0.71%	11.75%	9.62%	-	4.36%
Research & Development	40.56M	19.78M	46.42M	43.65M	45.78M	41.38M	39.35M	50.56M	61.36M	81.33M
R&D % of Revenue	-	-	-	1.63%	2.62%	0.47%	19.17%	19.48%	-	8.13%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-58.2M	-37M	-67.8M	-94.78M	-132.34M	-49.36M	-61.41M	-72.94M	-92.08M	-114.96M
Operating Margin %	-	-	-	-3.55%	-7.58%	-0.56%	-29.91%	-28.1%	-	-11.5%
Operating Income Growth %	-0.09%	0.36%	-0.83%	-0.4%	-0.4%	0.63%	-0.24%	-0.19%	-0.26%	-0.25%
EBITDA+	-57.45M	-36.33M	-67.25M	-93.36M	-130.16M	-48.1M	-61.34M	-72.82M	-92.02M	-114.93M
EBITDA Margin %	-	-	-	-3.49%	-7.46%	-0.54%	-29.88%	-28.05%	-	-11.49%
EBITDA Growth %	-0.08%	0.37%	-0.85%	-0.39%	-0.39%	0.63%	-0.28%	-0.19%	-0.26%	-0.25%
D&A (Non-Cash Add-back)	754K	670K	556K	1.42M	2.18M	1.25M	72K	118K	62K	26K
EBIT	-57.87M	-36.44M	-67.24M	-66.62M	-128.6M	-51.74M	-61.23M	-71.67M	-83.23M	-125.89M
Net Interest Income+	0	0	2K	-3.21M	-16.23M	-15.28M	-9.79M	-922K	2.08M	-413K
Interest Income	334K	562K	561K	2.6M	4.38M	515K	181K	1.22M	6.21M	4.15M
Interest Expense	0	0	559K	5.81M	20.61M	15.79M	9.97M	2.14M	4.14M	4.56M
Other Income/Expense	334K	562K	2K	22.35M	-16.87M	-18.17M	-9.79M	-875K	4.72M	-15.5M
Pretax Income+	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.53M	-71.2M	-73.81M	-87.37M	-130.45M
Pretax Margin %	-	-	-	-2.71%	-8.55%	-0.76%	-34.68%	-28.43%	-	-13.05%
Income Tax+	0	0	561K	0	0	194K	0	0	0	185K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.73M	-71.2M	-73.81M	-87.37M	-130.64M
Net Margin %	-	-	-	-2.71%	-8.55%	-0.77%	-34.68%	-28.43%	-	-13.06%
Net Income Growth %	-0.08%	0.37%	-0.86%	-0.07%	-1.06%	0.55%	-0.05%	-0.04%	-0.18%	-0.5%
Net Income (Continuing)	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.73M	-71.2M	-73.81M	-87.37M	-130.64M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19.32	-11.82	-21.18	-12.54	-27.22	-5.28	-4.92	-4.57	-3.96	-3.66
EPS Growth %	0.22%	0.39%	-0.79%	0.41%	-1.17%	0.81%	0.07%	0.07%	0.13%	0.08%
EPS (Basic)	-19.32	-11.82	-21.18	-12.54	-27.22	-5.28	-4.92	-4.57	-3.96	-3.66
Diluted Shares Outstanding	2.99M	3.08M	3.2M	5.78M	6.21M	12.78M	14.53M	16.14M	22.05M	35.71M
Basic Shares Outstanding	2.99M	3.08M	3.2M	5.78M	6.21M	12.78M	14.53M	16.14M	22.05M	35.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	110.84M	81.3M	87.79M	253.26M	84.96M	144.94M	105.74M	92.87M	143.68M	94.96M
Cash & Short-Term Investments	110.26M	80.9M	86.67M	249.65M	75.51M	141.23M	100.26M	87.89M	137.13M	88.82M
Cash Only	24.87M	32.35M	82.18M	129.87M	43.51M	67.78M	21.25M	74.93M	77.91M	88.82M
Short-Term Investments	85.39M	48.55M	4.5M	119.79M	31.99M	73.44M	79M	12.96M	59.22M	0
Accounts Receivable	154K	204K	0	306K	2.52M	239K	516K	31K	0	200K
Days Sales Outstanding	-	-	-	4.18	52.78	0.99	91.74	4.36	-	7.3
Inventory	0	0	0	327K	3.1M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	202.98	402.58	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	6.55M	5.94M
Total Non-Current Assets+	2.25M	2.33M	2M	23.98M	60.09M	9.41M	2.92M	2.18M	6.04M	6.58M
Property, Plant & Equipment	2.05M	1.42M	861K	1.37M	4.02M	3.14M	2.51M	1.88M	1.21M	1.44M
Fixed Asset Turnover	-	-	-	19.52x	4.34x	28.17x	0.82x	1.38x	-	6.96x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	21.58M	20.01M	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	6M	0	241K	0	0
Other Non-Current Assets	203K	917K	1.14M	1.03M	36.05M	274K	410K	58K	4.83M	5.14M
Total Assets+	113.09M	83.63M	89.79M	277.24M	145.05M	154.35M	108.66M	95.05M	149.72M	101.54M
Asset Turnover	-	-	-	0.10x	0.12x	0.57x	0.02x	0.03x	-	0.10x
Asset Growth %	0.15%	-0.26%	0.07%	2.09%	-0.48%	0.06%	-0.3%	-0.13%	0.58%	-0.32%
Total Current Liabilities+	10.11M	10.99M	17.13M	37.08M	29.89M	17.09M	18.59M	21.66M	26.38M	30.97M
Accounts Payable	3.94M	4.09M	9.19M	10.25M	9.65M	1.88M	2.3M	4.9M	7.18M	4.03M
Days Payables Outstanding	1.91K	2.23K	6.03K	6.36K	1.26K	20.28	-	-	-	-
Short-Term Debt	0	0	0	5.72M	0	0	0	275K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	710K	0	0
Other Current Liabilities	2.03M	3.99M	4.7M	11.88M	7.85M	5.93M	3.89M	11.14M	5.12M	6.25M
Current Ratio	10.96x	7.40x	5.13x	6.83x	2.84x	8.48x	5.69x	4.29x	5.45x	3.07x
Quick Ratio	10.96x	7.40x	5.13x	6.82x	2.74x	8.48x	5.69x	4.29x	5.45x	3.07x
Cash Conversion Cycle	-	-	-	-6.16K	-800.1	-	-	-	-	-
Total Non-Current Liabilities+	516K	341K	14.98M	115.86M	107.98M	21.98M	2.51M	26M	65.96M	99.46M
Long-Term Debt	0	0	14.83M	114.74M	103.62M	19.05M	249K	24.53M	40.09M	40.72M
Capital Lease Obligations	0	0	0	0	3.49M	2.93M	2.26M	1.47M	530K	535K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	516K	341K	151K	1.12M	870K	0	0	0	25.35M	58.2M
Total Liabilities	10.63M	11.33M	32.11M	152.94M	137.87M	39.08M	21.1M	47.66M	92.34M	130.43M
Total Debt+	0	0	14.83M	120.45M	107.53M	22.54M	3.18M	27.07M	41.56M	42.25M
Net Debt	-24.87M	-32.35M	-67.35M	-9.41M	64.02M	-45.24M	-18.07M	-47.87M	-36.35M	-46.56M
Debt / Equity	-	-	0.26x	0.97x	14.99x	0.20x	0.04x	0.57x	0.72x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-121.30x	-16.31x	-6.42x	-3.13x	-6.16x	-34.13x	-22.25x	-25.20x
Total Equity+	102.47M	72.3M	57.68M	124.3M	7.17M	115.27M	87.56M	47.39M	57.37M	-28.89M
Equity Growth %	0.15%	-0.29%	-0.2%	1.15%	-0.94%	15.07%	-0.24%	-0.46%	0.21%	-1.5%
Book Value per Share	34.22	23.46	18.02	21.52	1.15	9.02	6.02	2.94	2.60	-0.81
Total Shareholders' Equity	102.47M	72.3M	57.68M	124.3M	7.17M	115.27M	87.56M	47.39M	57.37M	-28.89M
Common Stock	4K	4K	5K	7K	8K	17K	19K	20K	3K	4K
Retained Earnings	-198.88M	-235.32M	-303.14M	-375.58M	-524.78M	-592.51M	-663.71M	-737.52M	-824.89M	-955.53M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	43K	29K	-2K	127K	14K	53K	34K	0	13K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-45.56M	-29.48M	-57.31M	-74.52M	-138.52M	-33.51M	-53.5M	-63.67M	-86.46M	-104.77M
Operating CF Margin %	-	-	-	-2.79%	-7.94%	-0.38%	-26.06%	-24.53%	-	-10.48%
Operating CF Growth %	-0.23%	0.35%	-0.94%	-0.3%	-0.86%	0.76%	-0.6%	-0.19%	-0.36%	-0.21%
Net Income	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.73M	-71.2M	-73.81M	-87.37M	-130.64M
Depreciation & Amortization	754K	670K	556K	1.42M	2.18M	1.25M	72K	-36K	62K	26K
Stock-Based Compensation	10.09M	6.29M	5.03M	6.67M	8.54M	8.12M	7.71M	6.05M	5.86M	7.34M
Deferred Taxes	0	0	0	-25.64M	641K	2.89M	0	0	0	0
Other Non-Cash Items	310K	-140K	223K	1.81M	7.13M	10.32M	9.33M	228K	-4.06M	14.78M
Working Capital Changes	1.16M	139K	4.68M	13.65M	-7.8M	11.63M	584K	3.9M	-957K	3.72M
Change in Receivables	0	0	0	-306K	-2.22M	2.29M	-277K	485K	31K	-200K
Change in Inventory	0	0	0	-327K	-2.77M	3.1M	0	0	0	0
Change in Payables	863K	153K	5.05M	1.05M	-598K	-7.98M	623K	2.6M	2.28M	-3.16M
Cash from Investing+	-27.06M	36.97M	43.95M	-138.38M	89.61M	-47.36M	87K	66.19M	-44.45M	59.97M
Capital Expenditures	-211K	-39K	0	-23.51M	-7K	-33K	-196K	0	0	-28K
CapEx % of Revenue	-	-	-	0.88%	0%	0%	0.1%	-	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-264K	41K	0	-21.92M	-7.13M	-10.32M	-9.33M	0	0	5K
Cash from Financing+	63.59M	-5K	63.18M	261.16M	-2.44M	69.63M	6.88M	51.78M	134.19M	54.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-404K	-5K	304K	809K	63K	937K	162K	282K	57K	40.71M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-45.77M	-29.52M	-57.31M	-98.02M	-138.53M	-33.54M	-53.7M	-63.67M	-86.46M	-104.8M
FCF Margin %	-	-	-	-3.67%	-7.94%	-0.38%	-26.16%	-24.53%	-	-10.48%
FCF Growth %	-0.16%	0.35%	-0.94%	-0.71%	-0.41%	0.76%	-0.6%	-0.19%	-0.36%	-0.21%
FCF per Share	-15.29	-9.58	-17.90	-16.97	-22.29	-2.62	-3.69	-3.95	-3.92	-2.93
FCF Conversion (FCF/Net Income)	0.79x	0.81x	0.85x	1.03x	0.93x	0.49x	0.75x	0.86x	0.99x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	3.36M	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-60.52%	-41.7%	-104.33%	-79.61%	-226.98%	-110.62%	-70.21%	-109.39%	-166.79%	-917.36%
Return on Invested Capital (ROIC)	-65.9%	-47.22%	-335.84%	-135.12%	-106.68%	-52.43%	-66.02%	-158.54%	-672.31%	-
Gross Margin	-	-	-	97.8%	83.92%	61.88%	100%	100%	-	100%
Net Margin	-	-	-	-271.11%	-854.77%	-76.51%	-3468.1%	-2843.3%	-	-1306.37%
Debt / Equity	-	-	0.26x	0.97x	14.99x	0.20x	0.04x	0.57x	0.72x	-
Interest Coverage	-	-	-121.30x	-16.31x	-6.42x	-3.13x	-6.16x	-34.13x	-22.25x	-25.20x
FCF Conversion	0.79x	0.81x	0.85x	1.03x	0.93x	0.49x	0.75x	0.86x	0.99x	0.80x
Revenue Growth	-	-	-	-	-34.67%	407.08%	-97.68%	26.45%	-100%	-

Revenue by Segment

	2018	2019	2020	2021	2022
Sale of COPIKTRA license and related assets	-	-	-	-	2.6M
Sale of COPIKTRA license and related assets Growth	-	-	-	-	-
Copiktra license and related assets	-	-	-	1.45M	-
Copiktra license and related assets Growth	-	-	-	-	-
Government rebates and other incentives	-	-	-	67K	-
Government rebates and other incentives Growth	-	-	-	-	-
Returns	-	-	-	31K	-
Returns Growth	-	-	-	-	-
Trade discounts and allowances	-	-	-	23K	-
Trade discounts and allowances Growth	-	-	-	-	-
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees	88K	255K	2.08M	-	-
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees Growth	-	189.77%	713.73%	-	-
Product Revenue Reserves And Allowances Government Rebates And Other Incentives	157K	372K	67K	-	-
Product Revenue Reserves And Allowances Government Rebates And Other Incentives Growth	-	136.94%	-81.99%	-	-
Product Revenue And Allowances Returns	2K	76K	31K	-	-
Product Revenue And Allowances Returns Growth	-	3700.00%	-59.21%	-	-
Product Revenue Reserves And Allowances Trade Discounts And Allowances	29K	111K	23K	-	-
Product Revenue Reserves And Allowances Trade Discounts And Allowances Growth	-	282.76%	-79.28%	-	-

Frequently Asked Questions

Growth & Financials

Verastem, Inc. (VSTM) reported $13.4M in revenue for fiscal year 2024.

Verastem, Inc. (VSTM) grew revenue by 0.0% over the past year. Growth has been modest.

Verastem, Inc. (VSTM) reported a net loss of $241.1M for fiscal year 2024.

Dividend & Returns

Verastem, Inc. (VSTM) has a return on equity (ROE) of -917.4%. Negative ROE indicates the company is unprofitable.

Verastem, Inc. (VSTM) had negative free cash flow of $132.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Verastem, Inc. (VSTM) 10-Year Financial Performance & Capital Metrics

VSTM • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $10M
EBITDA -$115M -24.9%
Net Income -$131M -49.5%
EPS (Diluted) -3.66 +7.6%
Gross Margin 100%
EBITDA Margin -1149.3%
Operating Margin -1149.56%
Net Margin -1306.37%
ROE -917.36% -450.0%
ROIC -
Debt/Equity -
Interest Coverage -25.20 -13.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Sales declining 10.5% over 5 years
✗Shares diluted 61.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-10.54%

3Y69.51%

TTM33.79%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-157.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM-45.14%

ROCE

10Y Avg-72.56%

5Y Avg-78.91%

3Y Avg-100.48%

Latest-118.57%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	26.72M	17.46M	88.52M	2.05M	2.6M	0	10M
Revenue Growth %	-	-	-	-	-0.35%	4.07%	-0.98%	0.26%	-1%	-
Cost of Goods Sold+	754K	670K	556K	588K	2.81M	33.74M	0	0	0	0
COGS % of Revenue	-	-	-	0.02%	0.16%	0.38%	-	-	-	-
Gross Profit+	-754K	-670K	-556K	26.13M	14.65M	54.77M	2.05M	2.6M	0	10M
Gross Margin %	-	-	-	0.98%	0.84%	0.62%	1%	1%	-	1%
Gross Profit Growth %	-	0.11%	0.17%	48%	-0.44%	2.74%	-0.96%	0.26%	-1%	-
Operating Expenses+	58.2M	37M	67.8M	120.91M	146.99M	104.13M	63.46M	75.53M	92.08M	124.96M
OpEx % of Revenue	-	-	-	4.53%	8.42%	1.18%	30.91%	29.1%	-	12.5%
Selling, General & Admin	17.63M	17.22M	21.38M	77.27M	101.21M	62.76M	24.11M	24.98M	30.73M	43.62M
SG&A % of Revenue	-	-	-	2.89%	5.8%	0.71%	11.75%	9.62%	-	4.36%
Research & Development	40.56M	19.78M	46.42M	43.65M	45.78M	41.38M	39.35M	50.56M	61.36M	81.33M
R&D % of Revenue	-	-	-	1.63%	2.62%	0.47%	19.17%	19.48%	-	8.13%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-58.2M	-37M	-67.8M	-94.78M	-132.34M	-49.36M	-61.41M	-72.94M	-92.08M	-114.96M
Operating Margin %	-	-	-	-3.55%	-7.58%	-0.56%	-29.91%	-28.1%	-	-11.5%
Operating Income Growth %	-0.09%	0.36%	-0.83%	-0.4%	-0.4%	0.63%	-0.24%	-0.19%	-0.26%	-0.25%
EBITDA+	-57.45M	-36.33M	-67.25M	-93.36M	-130.16M	-48.1M	-61.34M	-72.82M	-92.02M	-114.93M
EBITDA Margin %	-	-	-	-3.49%	-7.46%	-0.54%	-29.88%	-28.05%	-	-11.49%
EBITDA Growth %	-0.08%	0.37%	-0.85%	-0.39%	-0.39%	0.63%	-0.28%	-0.19%	-0.26%	-0.25%
D&A (Non-Cash Add-back)	754K	670K	556K	1.42M	2.18M	1.25M	72K	118K	62K	26K
EBIT	-57.87M	-36.44M	-67.24M	-66.62M	-128.6M	-51.74M	-61.23M	-71.67M	-83.23M	-125.89M
Net Interest Income+	0	0	2K	-3.21M	-16.23M	-15.28M	-9.79M	-922K	2.08M	-413K
Interest Income	334K	562K	561K	2.6M	4.38M	515K	181K	1.22M	6.21M	4.15M
Interest Expense	0	0	559K	5.81M	20.61M	15.79M	9.97M	2.14M	4.14M	4.56M
Other Income/Expense	334K	562K	2K	22.35M	-16.87M	-18.17M	-9.79M	-875K	4.72M	-15.5M
Pretax Income+	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.53M	-71.2M	-73.81M	-87.37M	-130.45M
Pretax Margin %	-	-	-	-2.71%	-8.55%	-0.76%	-34.68%	-28.43%	-	-13.05%
Income Tax+	0	0	561K	0	0	194K	0	0	0	185K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.73M	-71.2M	-73.81M	-87.37M	-130.64M
Net Margin %	-	-	-	-2.71%	-8.55%	-0.77%	-34.68%	-28.43%	-	-13.06%
Net Income Growth %	-0.08%	0.37%	-0.86%	-0.07%	-1.06%	0.55%	-0.05%	-0.04%	-0.18%	-0.5%
Net Income (Continuing)	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.73M	-71.2M	-73.81M	-87.37M	-130.64M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19.32	-11.82	-21.18	-12.54	-27.22	-5.28	-4.92	-4.57	-3.96	-3.66
EPS Growth %	0.22%	0.39%	-0.79%	0.41%	-1.17%	0.81%	0.07%	0.07%	0.13%	0.08%
EPS (Basic)	-19.32	-11.82	-21.18	-12.54	-27.22	-5.28	-4.92	-4.57	-3.96	-3.66
Diluted Shares Outstanding	2.99M	3.08M	3.2M	5.78M	6.21M	12.78M	14.53M	16.14M	22.05M	35.71M
Basic Shares Outstanding	2.99M	3.08M	3.2M	5.78M	6.21M	12.78M	14.53M	16.14M	22.05M	35.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	110.84M	81.3M	87.79M	253.26M	84.96M	144.94M	105.74M	92.87M	143.68M	94.96M
Cash & Short-Term Investments	110.26M	80.9M	86.67M	249.65M	75.51M	141.23M	100.26M	87.89M	137.13M	88.82M
Cash Only	24.87M	32.35M	82.18M	129.87M	43.51M	67.78M	21.25M	74.93M	77.91M	88.82M
Short-Term Investments	85.39M	48.55M	4.5M	119.79M	31.99M	73.44M	79M	12.96M	59.22M	0
Accounts Receivable	154K	204K	0	306K	2.52M	239K	516K	31K	0	200K
Days Sales Outstanding	-	-	-	4.18	52.78	0.99	91.74	4.36	-	7.3
Inventory	0	0	0	327K	3.1M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	202.98	402.58	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	6.55M	5.94M
Total Non-Current Assets+	2.25M	2.33M	2M	23.98M	60.09M	9.41M	2.92M	2.18M	6.04M	6.58M
Property, Plant & Equipment	2.05M	1.42M	861K	1.37M	4.02M	3.14M	2.51M	1.88M	1.21M	1.44M
Fixed Asset Turnover	-	-	-	19.52x	4.34x	28.17x	0.82x	1.38x	-	6.96x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	21.58M	20.01M	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	6M	0	241K	0	0
Other Non-Current Assets	203K	917K	1.14M	1.03M	36.05M	274K	410K	58K	4.83M	5.14M
Total Assets+	113.09M	83.63M	89.79M	277.24M	145.05M	154.35M	108.66M	95.05M	149.72M	101.54M
Asset Turnover	-	-	-	0.10x	0.12x	0.57x	0.02x	0.03x	-	0.10x
Asset Growth %	0.15%	-0.26%	0.07%	2.09%	-0.48%	0.06%	-0.3%	-0.13%	0.58%	-0.32%
Total Current Liabilities+	10.11M	10.99M	17.13M	37.08M	29.89M	17.09M	18.59M	21.66M	26.38M	30.97M
Accounts Payable	3.94M	4.09M	9.19M	10.25M	9.65M	1.88M	2.3M	4.9M	7.18M	4.03M
Days Payables Outstanding	1.91K	2.23K	6.03K	6.36K	1.26K	20.28	-	-	-	-
Short-Term Debt	0	0	0	5.72M	0	0	0	275K	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	710K	0	0
Other Current Liabilities	2.03M	3.99M	4.7M	11.88M	7.85M	5.93M	3.89M	11.14M	5.12M	6.25M
Current Ratio	10.96x	7.40x	5.13x	6.83x	2.84x	8.48x	5.69x	4.29x	5.45x	3.07x
Quick Ratio	10.96x	7.40x	5.13x	6.82x	2.74x	8.48x	5.69x	4.29x	5.45x	3.07x
Cash Conversion Cycle	-	-	-	-6.16K	-800.1	-	-	-	-	-
Total Non-Current Liabilities+	516K	341K	14.98M	115.86M	107.98M	21.98M	2.51M	26M	65.96M	99.46M
Long-Term Debt	0	0	14.83M	114.74M	103.62M	19.05M	249K	24.53M	40.09M	40.72M
Capital Lease Obligations	0	0	0	0	3.49M	2.93M	2.26M	1.47M	530K	535K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	516K	341K	151K	1.12M	870K	0	0	0	25.35M	58.2M
Total Liabilities	10.63M	11.33M	32.11M	152.94M	137.87M	39.08M	21.1M	47.66M	92.34M	130.43M
Total Debt+	0	0	14.83M	120.45M	107.53M	22.54M	3.18M	27.07M	41.56M	42.25M
Net Debt	-24.87M	-32.35M	-67.35M	-9.41M	64.02M	-45.24M	-18.07M	-47.87M	-36.35M	-46.56M
Debt / Equity	-	-	0.26x	0.97x	14.99x	0.20x	0.04x	0.57x	0.72x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-121.30x	-16.31x	-6.42x	-3.13x	-6.16x	-34.13x	-22.25x	-25.20x
Total Equity+	102.47M	72.3M	57.68M	124.3M	7.17M	115.27M	87.56M	47.39M	57.37M	-28.89M
Equity Growth %	0.15%	-0.29%	-0.2%	1.15%	-0.94%	15.07%	-0.24%	-0.46%	0.21%	-1.5%
Book Value per Share	34.22	23.46	18.02	21.52	1.15	9.02	6.02	2.94	2.60	-0.81
Total Shareholders' Equity	102.47M	72.3M	57.68M	124.3M	7.17M	115.27M	87.56M	47.39M	57.37M	-28.89M
Common Stock	4K	4K	5K	7K	8K	17K	19K	20K	3K	4K
Retained Earnings	-198.88M	-235.32M	-303.14M	-375.58M	-524.78M	-592.51M	-663.71M	-737.52M	-824.89M	-955.53M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	43K	29K	-2K	127K	14K	53K	34K	0	13K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-45.56M	-29.48M	-57.31M	-74.52M	-138.52M	-33.51M	-53.5M	-63.67M	-86.46M	-104.77M
Operating CF Margin %	-	-	-	-2.79%	-7.94%	-0.38%	-26.06%	-24.53%	-	-10.48%
Operating CF Growth %	-0.23%	0.35%	-0.94%	-0.3%	-0.86%	0.76%	-0.6%	-0.19%	-0.36%	-0.21%
Net Income	-57.87M	-36.44M	-67.8M	-72.43M	-149.21M	-67.73M	-71.2M	-73.81M	-87.37M	-130.64M
Depreciation & Amortization	754K	670K	556K	1.42M	2.18M	1.25M	72K	-36K	62K	26K
Stock-Based Compensation	10.09M	6.29M	5.03M	6.67M	8.54M	8.12M	7.71M	6.05M	5.86M	7.34M
Deferred Taxes	0	0	0	-25.64M	641K	2.89M	0	0	0	0
Other Non-Cash Items	310K	-140K	223K	1.81M	7.13M	10.32M	9.33M	228K	-4.06M	14.78M
Working Capital Changes	1.16M	139K	4.68M	13.65M	-7.8M	11.63M	584K	3.9M	-957K	3.72M
Change in Receivables	0	0	0	-306K	-2.22M	2.29M	-277K	485K	31K	-200K
Change in Inventory	0	0	0	-327K	-2.77M	3.1M	0	0	0	0
Change in Payables	863K	153K	5.05M	1.05M	-598K	-7.98M	623K	2.6M	2.28M	-3.16M
Cash from Investing+	-27.06M	36.97M	43.95M	-138.38M	89.61M	-47.36M	87K	66.19M	-44.45M	59.97M
Capital Expenditures	-211K	-39K	0	-23.51M	-7K	-33K	-196K	0	0	-28K
CapEx % of Revenue	-	-	-	0.88%	0%	0%	0.1%	-	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-264K	41K	0	-21.92M	-7.13M	-10.32M	-9.33M	0	0	5K
Cash from Financing+	63.59M	-5K	63.18M	261.16M	-2.44M	69.63M	6.88M	51.78M	134.19M	54.78M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-404K	-5K	304K	809K	63K	937K	162K	282K	57K	40.71M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-45.77M	-29.52M	-57.31M	-98.02M	-138.53M	-33.54M	-53.7M	-63.67M	-86.46M	-104.8M
FCF Margin %	-	-	-	-3.67%	-7.94%	-0.38%	-26.16%	-24.53%	-	-10.48%
FCF Growth %	-0.16%	0.35%	-0.94%	-0.71%	-0.41%	0.76%	-0.6%	-0.19%	-0.36%	-0.21%
FCF per Share	-15.29	-9.58	-17.90	-16.97	-22.29	-2.62	-3.69	-3.95	-3.92	-2.93
FCF Conversion (FCF/Net Income)	0.79x	0.81x	0.85x	1.03x	0.93x	0.49x	0.75x	0.86x	0.99x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	3.36M	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-60.52%	-41.7%	-104.33%	-79.61%	-226.98%	-110.62%	-70.21%	-109.39%	-166.79%	-917.36%
Return on Invested Capital (ROIC)	-65.9%	-47.22%	-335.84%	-135.12%	-106.68%	-52.43%	-66.02%	-158.54%	-672.31%	-
Gross Margin	-	-	-	97.8%	83.92%	61.88%	100%	100%	-	100%
Net Margin	-	-	-	-271.11%	-854.77%	-76.51%	-3468.1%	-2843.3%	-	-1306.37%
Debt / Equity	-	-	0.26x	0.97x	14.99x	0.20x	0.04x	0.57x	0.72x	-
Interest Coverage	-	-	-121.30x	-16.31x	-6.42x	-3.13x	-6.16x	-34.13x	-22.25x	-25.20x
FCF Conversion	0.79x	0.81x	0.85x	1.03x	0.93x	0.49x	0.75x	0.86x	0.99x	0.80x
Revenue Growth	-	-	-	-	-34.67%	407.08%	-97.68%	26.45%	-100%	-

Revenue by Segment

	2018	2019	2020	2021	2022
Sale of COPIKTRA license and related assets	-	-	-	-	2.6M
Sale of COPIKTRA license and related assets Growth	-	-	-	-	-
Copiktra license and related assets	-	-	-	1.45M	-
Copiktra license and related assets Growth	-	-	-	-	-
Government rebates and other incentives	-	-	-	67K	-
Government rebates and other incentives Growth	-	-	-	-	-
Returns	-	-	-	31K	-
Returns Growth	-	-	-	-	-
Trade discounts and allowances	-	-	-	23K	-
Trade discounts and allowances Growth	-	-	-	-	-
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees	88K	255K	2.08M	-	-
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees Growth	-	189.77%	713.73%	-	-
Product Revenue Reserves And Allowances Government Rebates And Other Incentives	157K	372K	67K	-	-
Product Revenue Reserves And Allowances Government Rebates And Other Incentives Growth	-	136.94%	-81.99%	-	-
Product Revenue And Allowances Returns	2K	76K	31K	-	-
Product Revenue And Allowances Returns Growth	-	3700.00%	-59.21%	-	-
Product Revenue Reserves And Allowances Trade Discounts And Allowances	29K	111K	23K	-	-
Product Revenue Reserves And Allowances Trade Discounts And Allowances Growth	-	282.76%	-79.28%	-	-

Frequently Asked Questions

Growth & Financials

Verastem, Inc. (VSTM) reported $13.4M in revenue for fiscal year 2024.

Verastem, Inc. (VSTM) grew revenue by 0.0% over the past year. Growth has been modest.

Verastem, Inc. (VSTM) reported a net loss of $241.1M for fiscal year 2024.

Dividend & Returns

Verastem, Inc. (VSTM) has a return on equity (ROE) of -917.4%. Negative ROE indicates the company is unprofitable.

Verastem, Inc. (VSTM) had negative free cash flow of $132.7M in fiscal year 2024, likely due to heavy capital investments.